PHARMACISTS are being given the green-light to substitute specified Orencia (abatacept) products without approval from the prescriber under a Serious Scarcity Substitution Instrument (SSSI) issued by the Therapeutic Goods Administration (TGA).
Under the SSSI both Orencia abatacept (rch) 125 mg single dose syringe subcutaneous ultrasafe passive needle guard and flang extender, and Orencia abatacept (rch) 125 mg single dose ClickJect prefilled autoinjector, products are "effectively interchangeable at the pharmacy level".
The SSSI will remain in force until 30 Apr, unless revoked at an earlier date if the serious scarcity is resolved.
CLICK HERE for more information.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Feb 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Feb 22
